Inside the research
Novanta Inc.
NOVT Research profile · latest available data
Price overview
$143.93
▲ +2.40 (+1.7%)
| 52w hi | $168.75 |
|---|---|
| 52w lo | $99.22 |
| Vol | 287.80K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.06
| Short | -0.37 |
|---|---|
| Medium | +0.32 |
| Long | +0.40 |
computed 2026-09-27
Key fundamentals
Novanta Inc.
Technology · Scientific & Technical Instruments
| Market cap | $5.44B |
|---|---|
| Enterprise value | $5.01B |
| Trailing P/E | 91.09x |
| Forward P/E | 32.96x |
| EV / EBITDA | 27.69x |
| P / S (ttm) | 5.29x |
| Profit margin | 6.0% |
| Return on equity | 5.1% |
| Revenue growth | +10.3% |
| Earnings growth | +150.0% |
| Debt / equity | 17.67 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.20 | |
| Sector | +0.19 | |
| Technical | -0.18 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
Risk Metrics
| Beta vs SPX | 1.67 |
|---|---|
| Corr SPX | 0.58 |
| Annual vol | 46.2% |
| Annual ret | +1.0% |
| Sharpe | 0.02 |
| Max DD | -45.7% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-07-27 | Acquisition / Disposition, Material Obligation… | read |
| 2026-06-09 | Material Agreement, Securities Issuance… | read |
| 2026-06-09 | Material Agreement, Reg FD Disclosure… | read |
| 2026-05-29 | Shareholder Vote | read |
| 2026-05-15 | Material Agreement, Material Obligation… | read |
| 2026-05-11 | Earnings Release, Exhibits | read |
| 2026-02-23 | Earnings Release, Exhibits | read |
| 2025-12-01 | Reg FD Disclosure | read |
| 2025-11-13 | Reg FD Disclosure | read |
| 2025-11-12 | Material Agreement, Material Obligation… | read |
| 2025-11-03 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Glastra Matthijs | Chief Executive Officer | Sell | 437 | $71.54K |
| 2026-07-02 | Glastra Matthijs | Chief Executive Officer | Sell | 3.02K | $484.23K |
| 2026-07-02 | Glastra Matthijs | Chief Executive Officer | Sell | 200 | $32.84K |
| 2026-07-02 | Glastra Matthijs | Chief Executive Officer | Sell | 1.67K | $269.66K |
| 2026-07-02 | Glastra Matthijs | Chief Executive Officer | Sell | 1.17K | $189.07K |
| 2026-06-02 | Glastra Matthijs | Chief Executive Officer | Sell | 500 | $83.09K |
| 2026-06-02 | Glastra Matthijs | Chief Executive Officer | Sell | 1.30K | $220.86K |
| 2026-06-02 | Glastra Matthijs | Chief Executive Officer | Sell | 2.84K | $479.45K |
| 2026-06-02 | Glastra Matthijs | Chief Executive Officer | Sell | 1.42K | $238.11K |
| 2026-06-02 | Glastra Matthijs | Chief Executive Officer | Sell | 38 | $6.26K |
Flow & Concentration
| Insider 180d net | -$4.97M |
|---|---|
| Insider buys / sells | 0 / 18 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 95.8% |
| HHI | 2,064 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Millennium Management | $26.70M | 391.12K |
| AQR Capital Management | $15.23M | 95.25K |
| Bridgewater Associates | $14.62M | 90.12K |
| State Street Corp | $11.86M | 174.00K |
| Citadel Advisors | $11.61M | 170.09K |
| Fidelity / FMR LLC | $2.37M | 14.62K |
| Capital Research / Capital World | $764.92K | 11.35K |
| T. Rowe Price Group | $360.57K | 2.22M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $980.60M | +10.1% | |
| Gross profit | $435.28M | +7.1% | |
| Operating income | $94.01M | +4.1% | |
| Net income | $64.09M | +6.3% | |
| Cash from ops | $120.08M | +7.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $142.28 | $145.24 | $140.57 | $143.93 | 287.80K |
| Sep 24 | $143.75 | $143.79 | $139.77 | $141.53 | 250.30K |
| Sep 23 | $143.42 | $146.00 | $141.09 | $144.43 | 370.70K |
| Sep 22 | $136.91 | $144.41 | $135.08 | $144.17 | 776.80K |
| Sep 21 | $134.05 | $135.52 | $132.00 | $134.31 | 321.50K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →